5-(4-isopropylphenyl)-1,3,4-oxadiazol-2-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 5-(4-isopropylphenyl)-1,3,4-oxadiazol-2-ol
• 英文别名: 5-(4-propan-2-ylphenyl)-3H-1,3,4-oxadiazol-2-one
• 化学式: C₁₁H₁₂N₂O₂
• 分子量: 204.228
• InChiKey: BMHMAEDSRHFCIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(4-isopropylphenyl)-1,3,4-oxadiazol-2-ol 、 sodium hydroxide 在 四丁基溴化铵 methyl 、 水 、 hexanes 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以to provide methyl 4-{[5-(4-isopropylphenyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl]methyl}benzoate (0.65 g, 93%)的产率得到methyl 4-{[5-(4-isopropylphenyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl]methyl}benzoate
  参考文献：
  名称：

  Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases

  摘要：

  本发明涉及使用本发明的化合物或组合物治疗或预防与mRNA中无义突变相关的疾病的方法、化合物和组合物。更具体地，本发明涉及用于抑制与mRNA中无义突变相关的过早翻译终止的方法、化合物和组合物。

  公开号：

  US09051342B2
• 作为产物：
  描述：

  4-异丙基苯甲酸 在 氯化亚砜 、 hydrazine hydrate 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 19.0h， 生成 5-(4-isopropylphenyl)-1,3,4-oxadiazol-2-ol
  参考文献：
  名称：

  5-Phenyl-1,3,4-oxadiazol-2(3H)-ones Are Potent Inhibitors of Notum Carboxylesterase Activity Identified by the Optimization of a Crystallographic Fragment Screening Hit

  摘要：

  Carboxylesterase Notum is a negative regulator of the Wnt signaling pathway. There is an emerging understanding of the role Notum plays in disease, supporting the need to discover new small-molecule inhibitors. A crystallographic X-ray fragment screen was performed, which identified fragment hit 1,2,3-triazole 7 as an attractive starting point for a structure-based drug design hit-to-lead program. Optimization of 7 identified oxadiazol-2-one 23dd as a preferred example with properties consistent with druglike chemical space. Screening 23dd in a cell-based TCF/LEF reporter gene assay restored the activation of Wnt signaling in the presence of Notum. Mouse pharmacokinetic studies with oral administration of 23dd demonstrated good plasma exposure and partial blood-brain barrier penetration. Significant progress was made in developing fragment hit 7 into lead 23dd (>600-fold increase in activity), making it suitable as a new chemical tool for exploring the role of Notum-mediated regulation of Wnt signaling.

  DOI：

  10.1021/acs.jmedchem.0c01391

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：UCL BUSINESS LTD

  公开号：WO2020043866A1

  公开（公告）日：2020-03-05

  A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)

  一种用于治疗通过抑制公式（I）中的Notum改善的疾病的化合物：（I）
• TREATMENT AND PREVENTION OF NEUROPATHIC PAIN WITH P2Y14 ANTAGONISTS
  申请人：Saint Louis University

  公开号：US20210024489A1

  公开（公告）日：2021-01-28

  Disclosed herein are methods for treating neuropathic pain in a subject in need thereof. The methods include: administering to a subject in need thereof a therapeutically effective amount of an antagonist of P2Y14.

  本文公开了治疗神经病理性疼痛的方法，包括向需要的受试者施用P2Y14的拮抗剂的治疗有效量。
• Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases
  申请人：Almstead Neil

  公开号：US20080280869A1

  公开（公告）日：2008-11-13

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及通过给予本发明的化合物或组合物来治疗或预防与mRNA中无意义突变相关的疾病的方法、化合物和组合物。更具体地说，本发明涉及用于抑制与mRNA中无意义突变相关的早期翻译终止的方法、化合物和组合物。
• PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES
  申请人：PTC THERAPEUTICS, INC.

  公开号：US20150274674A1

  公开（公告）日：2015-10-01

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及使用本发明中的化合物或组合物治疗或预防与mRNA中的无义突变相关的疾病的方法、化合物和组合物。更具体地说，本发明涉及用于抑制与mRNA中的无意义突变相关的早期翻译终止的方法、化合物和组合物。
• Pyrrol derivatives, uses thereof
  申请人：PTC Therapeutics, Inc.

  公开号：EP2316452A1

  公开（公告）日：2011-05-04

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及通过施用本发明的化合物或组合物治疗或预防与 mRNA 中无义突变相关的疾病的方法、化合物和组合物。更具体地说，本发明涉及抑制与 mRNA 中无义突变相关的过早翻译终止的方法、化合物和组合物。